Avid Bioservices Inc (CDMO)

[pphmtoolong]

IFU, you make Peregrine sound like a pyramid scheme. If so, why do they need all those lab studies and clinical trials?

Everyone who know anything about the drug development business knows it is a lengthy and expensive proposition. Everyone knows many, if not most, drug development programs come to nothing.

At this point Peregrine has no debt, 60 million in the bank, a profitable little business in Avid, and Bavituximab.

In case you missed it, Bavituximab is approximately 2/3 through Phase III trials.

Oh, and maybe you missed the research collaborations announced recently with the world famous Memorial Sloan Kettering institute.

Or perhaps, you missed the Astrozeneca-Peregrine joint trial featuring Bavituximab.

Complaining about the dilution that has financed the process that has brought us to this point seems odd.

GLTA, Especially Bavi-arm Sunrise Patients,

Paul